A “PET” topic in primary mediastinal large B-cell lymphoma: positive or negative, and how to handle it in the end

References

• Gaulard P, Harris NL, Pileri SA, et al. Primary mediastinal (thymic) large B-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. World Health Organization classification of tumors of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008. pp 250– 251.
   Google Scholar
• Rieger M, Osterborg A, Pettengell R, et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol 2011;22:664–670.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos TP, Pangalis GA, Katsigiannis A, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist 2012;17:239–249.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Stefoni V, Finolezzi E, et al. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. Clin Lymphoma Myeloma 2009;9:381–385.
   PubMedGoogle Scholar
• Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 2013;368:1408–1416.
   PubMed Web of Science ®Google Scholar
• Pohlen M, Gerth HU, Liersch R, et al. Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in Burkitt's and primary mediastinal large B-cell lymphoma. Am J Hematol 2011;86:61–64.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos TP, Prassopoulos VK. Clinical implications of the role of 18FDG-PET/CT in malignant lymphomas. In: Gouliamos AD, Andreou J, Kosmidis P, editors. Imaging in clinical oncology. Milan: Springer-Verlag Italia; 2014. pp 249–265.
   Google Scholar
• Gallamini A, Kostakoglou L. Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials? Blood 2012;120:4913–4920.
   PubMed Web of Science ®Google Scholar
• Dührsen U, Hüttmann A, Jöckel KH, et al. Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas– the PETAL trial. Leuk Lymphoma 2009;50:1757–1760.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Hofman MS, Seymour JF, et al. The utility and limitations of 18F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review. Leuk Lymphoma 2015;56:49–56.
   PubMed Web of Science ®Google Scholar
• Meignan M, Gallamini A, Itti E, et al. Report on the third international workshop on interim positron emission tomography in lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. Leuk Lymphoma 2012;53:1876–1881.
   PubMed Web of Science ®Google Scholar
• Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma:consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571–578.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Schoder H, Teruya-Feldstein J, et al. Risk-adapted dose-dense immnochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol 2010;28:1896–1903.
   PubMed Web of Science ®Google Scholar
• Moskowitz C, Hamlin PA, Maragulia J, et al. Sequential dose-dense RCHOP followed by ICE consolidation (MSKCC protocol 01-142) without radiotherapy for patients with primary mediastinal large B-cell lymphoma. Blood 2010;116(Suppl. 1): Abstract 420.
   PubMed Web of Science ®Google Scholar
• Avigdor A, Sirotkin T, Kedmi M, et al. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma. Ann Hematol 2014 Mar 5. [Epub ahead of print]
   Web of Science ®Google Scholar
• Filippi AR, Piva C, Giunta F, et al. Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy. Int J Radiat Oncol Biol Phy. 2013;87:311–316.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos TP, Angelopoulou MK, Rondogianni P, et al. The role of PET/CT after rituximab-CHOP (R-CHOP) in primary mediastinal large B-cell lymphoma (PMLBCL): response assessment, prognostic significance and implications for subsequent radiotherapy (RT). Haematologica 2013;98(Suppl. 1): Abstract 135.
   Google Scholar
• Savage KJ, Yenson PR, Shenkier T, et al. The outcome of primary mediastinal large B-cell lymphoma (PMBCL) in the R-CHOP treatment era. Blood 2012;120(Suppl. 1): Abstract 303.
   PubMed Web of Science ®Google Scholar
• Martelli M, Ceriani L, Zucca E, et al. [18F] fluorodeoxy-glucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 study. J Clin Oncol 2014 5 May. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Casadei B, Pellegrini C, et al. The role of rituximab and PET in the treatment of primary mediastinal B-cell lymphoma. Hematol Oncol 2013;31(Suppl. 1): Abstract 128.
   Google Scholar
• Martelli M, Zucca E, Gospodarowicz M, et al. A randomized, multicentre, two-arm phase III comparative study assessing the role of mediastinal radiotherapy after rituximab-containing chemotherapy regimens to patients with newly diagnosed primary mediastinal large B-cell lymphoma (PMLBCL): the IELSG-37 study. Hematol Oncol 2013;31(Suppl. 1): Abstract 140.
   Google Scholar